Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
7.94
+0.61 (8.32%)
At close: Sep 18, 2025, 4:00 PM EDT
7.91
-0.03 (-0.38%)
After-hours: Sep 18, 2025, 7:32 PM EDT
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $25.88M in the quarter ending June 30, 2025, with 481.73% growth. This brings the company's revenue in the last twelve months to $62.02M, up 161.81% year-over-year. In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%.
Revenue (ttm)
$62.02M
Revenue Growth
+161.81%
P/S Ratio
6.21
Revenue / Employee
$1,051,186
Employees
59
Market Cap
445.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
| Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ZVRA News
- 13 hours ago - Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate) - GlobeNewsWire
- 14 days ago - Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewsWire
- 21 days ago - Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewsWire
- 23 days ago - Zevra Therapeutics to Participate at Upcoming Investor Conferences in September - GlobeNewsWire
- 5 weeks ago - Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Zevra Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call - GlobeNewsWire
- 7 weeks ago - Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C - GlobeNewsWire